Now we will move on to introducing our panel of witnesses today.
We have quite an entourage with us. First, from Canada's Research-Based Pharmaceutical Companies, we have Brigitte Nolet, who is a director of government relations and health policy, special division. She is from Hoffmann-La Roche Limited. We also have Declan Hamill, chief of staff and vice-president, legal affairs. From TEC Edmonton, we have Chris Lumb, chief executive officer. From Genome Canada, we have Pierre Meulien, president and chief executive officer. From Research In Motion, we have Morgan Elliot, director of government relations, and Robert Guay, director, intellectual property operations.
I will begin in the order we have before us. From Rx&D, Brigitte Nolet, please go ahead.